Sun F, Yao F, Zeng C, Zhao Y, Liang B, Li S
J Immunother Cancer. 2025; 13(2).
PMID: 39947814
PMC: 11831272.
DOI: 10.1136/jitc-2024-010126.
Xia H, Wang X, Zhang H, Wang K, Zhang L, Yang Y
Theranostics. 2025; 15(4):1255-1271.
PMID: 39816681
PMC: 11729547.
DOI: 10.7150/thno.102391.
Hu W, Cui X, Liu H, Li Z, Chen X, Wang Q
J Exp Clin Cancer Res. 2025; 44(1):3.
PMID: 39754188
PMC: 11697892.
DOI: 10.1186/s13046-024-03254-x.
Wu Y, Sun J, Huang J, Lu X
Sci Rep. 2024; 14(1):32096.
PMID: 39738531
PMC: 11685884.
DOI: 10.1038/s41598-024-83783-9.
Hashemi M, Abolghasemi Fard A, Pakshad B, Asheghabadi P, Hosseinkhani A, Hosseini A
Noncoding RNA Res. 2024; 11:1-21.
PMID: 39720352
PMC: 11665378.
DOI: 10.1016/j.ncrna.2024.11.006.
Co-culture models for investigating cellular crosstalk in the glioma microenvironment.
Niu X, Zhang Y, Wang Y
Cancer Pathog Ther. 2024; 2(4):219-230.
PMID: 39371093
PMC: 11447344.
DOI: 10.1016/j.cpt.2023.11.002.
EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma.
An Z, Fan Q, Wang L, Yoda H, Barata M, Jimenez-Morales D
Neuro Oncol. 2024; 27(2):383-397.
PMID: 39248287
PMC: 11812036.
DOI: 10.1093/neuonc/noae182.
HER3 receptor and its role in the therapeutic management of metastatic breast cancer.
Zhu M, Yu M, Meng Y, Yang J, Wang X, Li L
J Transl Med. 2024; 22(1):665.
PMID: 39020378
PMC: 11253420.
DOI: 10.1186/s12967-024-05445-8.
Eg5 and Diseases: From the Well-Known Role in Cancer to the Less-Known Activity in Noncancerous Pathological Conditions.
Ricci A, Carradori S, Cataldi A, Zara S
Biochem Res Int. 2024; 2024:3649912.
PMID: 38939361
PMC: 11211015.
DOI: 10.1155/2024/3649912.
Structural insights into the role and targeting of EGFRvIII.
Bagchi A, Stayrook S, Xenaki K, Starbird C, Doulkeridou S, El Khoulati R
Structure. 2024; 32(9):1367-1380.e6.
PMID: 38908376
PMC: 11380598.
DOI: 10.1016/j.str.2024.05.018.
EGFRvIII Confers Sensitivity to Saracatinib in a STAT5-Dependent Manner in Glioblastoma.
Blomquist M, Eghlimi R, Beniwal A, Grief D, Nascari D, Inge L
Int J Mol Sci. 2024; 25(11).
PMID: 38892466
PMC: 11172708.
DOI: 10.3390/ijms25116279.
Adaptations of membrane trafficking in cancer and tumorigenesis.
Evergren E, Mills I, Kennedy G
J Cell Sci. 2024; 137(10).
PMID: 38770683
PMC: 11166456.
DOI: 10.1242/jcs.260943.
Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.
Rahban M, Joushi S, Bashiri H, Saso L, Sheibani V
Front Chem. 2024; 11:1325214.
PMID: 38264122
PMC: 10804459.
DOI: 10.3389/fchem.2023.1325214.
A novel EGFR variant EGFRx maintains glioblastoma stem cells through STAT5.
Huang W, Li J, Zhu H, Qin X, Chen C, Wang B
Neuro Oncol. 2023; 26(1):85-99.
PMID: 37616578
PMC: 10768976.
DOI: 10.1093/neuonc/noad153.
CAR-NK cell therapy for glioblastoma: what to do next?.
Xiong Q, Zhu J, Zhang Y, Deng H
Front Oncol. 2023; 13:1192128.
PMID: 37404752
PMC: 10315652.
DOI: 10.3389/fonc.2023.1192128.
Nuclear export signal mutation of epidermal growth factor receptor enhances malignant phenotypes of cancer cells.
Nie L, Wang Y, Hsu J, Hou J, Chu Y, Chan L
Am J Cancer Res. 2023; 13(4):1209-1239.
PMID: 37168336
PMC: 10164793.
Comprehensive pan-cancer analysis of STAT3 as a prognostic and immunological biomarker.
He Z, Song B, Zhu M, Liu J
Sci Rep. 2023; 13(1):5069.
PMID: 36977736
PMC: 10050087.
DOI: 10.1038/s41598-023-31226-2.
Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation of EGFR for the Clinical Treatment of Glioblastoma.
Bhrdwaj A, Abdalla M, Pande A, Madhavi M, Chopra I, Soni L
Appl Biochem Biotechnol. 2023; 195(8):5094-5119.
PMID: 36976507
DOI: 10.1007/s12010-023-04430-z.
Increased EGFRvIII Epitope Accessibility after Tyrosine Kinase Inhibitor Treatment of Glioblastoma Cells Creates More Opportunities for Immunotherapy.
Treda C, Wlodarczyk A, Pacholczyk M, Rutkowska A, Stoczynska-Fidelus E, Kierasinska A
Int J Mol Sci. 2023; 24(5).
PMID: 36901782
PMC: 10001577.
DOI: 10.3390/ijms24054350.
Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures.
Ciechomska I, Wojnicki K, Wojtas B, Szadkowska P, Poleszak K, Kaza B
Cancers (Basel). 2023; 15(5).
PMID: 36900355
PMC: 10000883.
DOI: 10.3390/cancers15051562.